Physician profile
Hirsch S Mehta
NPI 1407099799
$494,085.14
in general payments reported to CMS, 2019-2025
54 companies · $93K in 2025
The $93K reported for 2025 was more than what 97% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58K · 2020: $47K · 2021: $56K · 2022: $117K · 2023: $71K · 2024: $52K · 2025: $93K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $190K · Consulting Fee: $11K · Food and Beverage: $8,381 · Travel and Lodging: $7,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $190,348.00 |
| Consulting Fee | $10,588.50 |
| Food and Beverage | $8,380.64 |
| Travel and Lodging | $7,143.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $115,866.48 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Merck Sharp & Dohme LLC | $67,657.63 | 2022-2025 | Verquvo, Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55,733.61 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $37,142.05 | 2019-2025 | Watchman Flx, Resonate El Icd Vr |
| Alnylam Pharmaceuticals INC. | $35,351.27 | 2019-2025 | Amvuttra, Onpattro |
| E.R. Squibb & Sons, L.L.C. | $29,975.86 | 2019-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $29,782.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $22,862.87 | 2019-2025 | Farxiga, Wainua, Andexxa |
| Pfizer INC. | $22,515.88 | 2019-2025 | |
| Lilly USA, LLC | $21,582.33 | 2020-2025 | Jardiance |
| Edwards Lifesciences Corporation | $16,238.61 | 2019-2024 | Sapien 3 Ultra Resilia |
| Akcea Therapeutics, INC. | $15,325.63 | 2019-2021 | |
| Bridgebio Pharma, INC. | $13,737.64 | 2025 | Attruby |
| Abbott Laboratories | $5,311.99 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Aveir, Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,355.48 | 2019-2025 | Lifevest |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $418.36 | 2019-2025 | |
| Abiomed | $308.53 | 2023-2025 | Impella |
| Medtronic Vascular, INC. | $273.55 | 2019 | |
| Cvrx, INC. | $256.12 | 2021-2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $249.23 | 2019-2024 | Xarelto |
| United Therapeutics Corporation | $214.17 | 2019-2025 | Tyvaso |
| Amgen INC. | $197.70 | 2019-2022 | |
| Medtronic, INC. | $181.05 | 2021-2025 | Abre |
| Biosense Webster, INC. | $166.86 | 2021-2023 | Carto 3 |
| Cathworks, INC. | $151.87 | 2019 | |
| Novo Nordisk INC | $151.30 | 2022-2025 | Ozempic, Rybelsus |
| Heartflow, INC. | $128.61 | 2019-2025 | |
| Getinge USA Sales, LLC | $120.46 | 2024-2025 | Vasoview Hemopro 2, Vasoview Hemopro 2 |
| Nuwellis, INC. | $108.28 | 2021-2023 | Aquadex Smartflow Console |
| Kestra Medical Technology Services, INC. | $95.37 | 2023-2025 | Assure Wcd |
| Esperion Therapeutics, INC. | $70.21 | 2021-2023 | Nexletol |
| Irhythm Technologies, INC. | $55.01 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Regeneron Healthcare Solutions, INC. | $54.92 | 2019 | |
| Scpharmaceuticals INC. | $52.46 | 2023 | |
| Daiichi Sankyo INC. | $47.26 | 2022-2025 | Injectafer |
| Kiniksa Pharmaceuticals, Ltd. | $39.18 | 2021-2022 | |
| Chiesi USA, INC. | $36.35 | 2020-2022 | |
| Terumo Medical Corporation | $33.13 | 2022 | |
| Impulse Dynamics (USA) INC. | $29.65 | 2022 | |
| Astellas Pharma US INC | $23.13 | 2019 | |
| Tactile Systems Technology INC | $22.95 | 2019 | |
| Amarin Pharma, INC. | $22.38 | 2020 | |
| Biotronik INC. | $21.60 | 2021 | |
| Gilead Sciences, INC. | $18.36 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $16.68 | 2023 | Inpefa |
| Sobi, INC | $15.89 | 2022 | |
| Trevena, INC. | $15.76 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $13.73 | 2024 | Arcalyst |
| Arbor Pharmaceuticals, INC. | $13.50 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.43 | 2019 | |
| Altathera Pharmaceuticals LLC | $10.40 | 2025 | Sotalol Hydrochloride |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hirsch Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.